Freeman Capital Management LLC

Representing Freeman Capital Management LLC, Read disclosures linked below first.

[Freeman Capital Management LLC @capital_freeman]

Today, FCM, our director candidates (including Dr. Scott Freeman), and Mr. Jake Freeman each reiterated their confidence in FCM’s plan by making a commitment to shareholders to not sell a single share of MindMed, should FCM’s nominees be elected.

https://t.co/asTH7uhYfr

Additional Information

FCM's and its nominees (Dr. Scott Freeman, Dr. Farzin Farzaneh, Mr. Vivek Jain, and Mr. Alexander Wodka) beneficially own, own, control or exercise direction over an aggregate of 1,009,181 common shares of MindMed (the “Shares”). FCM may be deemed to control an additional 359,357 Shares pursuant to a proxy coordination agreement.
Information in Support of Public Broadcast Solicitation

Shareholders are being asked at this time to execute a proxy in favour of FCM's nominees for election to the Board at the AGM or any other resolutions at the AGM, which has been formally scheduled for June 15, 2023. In connection with the AGM, FCM has filed definitive proxy materials with the Securities and Exchange Commission (the "Final FCM Circular") containing further disclosure concerning FCM's nominees for election to the Board at the AGM, together with additional details concerning the completion and return of forms of proxy and voting information forms ("VIFs") for use at the AGM. Shareholders of MindMed are urged to read the Materials filed today as well as the Final FCM Circular, when issued, because they will contain important information.
The below disclosure is provided pursuant to section 9.2(4) of National Instrument 51-102 – Continuous Disclosure Obligations in accordance with securities laws applicable to public broadcast solicitations.
This press release and any solicitation made by FCM in advance of the AGM is, or will be, as applicable, made by FCM and not by or on behalf of the management of MindMed.
Shareholders of MindMed are being asked at this time to execute proxies in favour of FCM's nominees for election to the Board at the AGM or any other matters to be considered at the AGM. FCM has issued the Final FCM Circular and FCM intends to make its solicitation primarily by mail, but proxies may also be solicited personally by telephone, email or other electronic means, as well as by newspaper or other media advertising or in person, by FCM, certain of its members, partners, directors, officers and employees, FCM's nominees or FCM's agents, including Okapi Partners LLC (“Okapi”), which has been retained by FCM as its strategic shareholder advisor and proxy solicitation agent. Pursuant to the agreement between Okapi and FCM, Okapi will receive a fee of up to $75,000, plus customary fees for each call to or from shareholders of MindMed, and will be reimbursed for certain out-of-pocket expenses, with all such costs to be borne by FCM. In addition, FCM may solicit proxies in reliance upon the public broadcast exemption to the solicitation requirements under applicable Canadian corporate and securities laws, by way of public broadcast, including press release, speech or publication, and in any other manner permitted under applicable Canadian laws. Any members, partners, directors, officers or employees of FCM and their affiliates or other persons who solicit proxies on behalf of FCM will do so for no additional compensation. The anticipated cost of FCM’s solicitation is estimated to be $400,000 plus disbursements. The costs incurred in the preparation and mailing of the Materials and the Final FCM Circular, and the solicitation of proxies by FCM will be borne by FCM, provided that, subject to applicable law, FCM may seek reimbursement from MindMed of FCM's out-of-pocket expenses, including proxy solicitation expenses and legal fees, incurred in connection with a successful reconstitution of the Board.
A registered shareholder of MindMed who has given a proxy may revoke the proxy at any time prior to use by:
(a) depositing an instrument in writing revoking the proxy, if the shareholder is an individual signed by the shareholder or his or her legal personal representative or trustee in bankruptcy, and if the shareholder is a corporation signed by the corporation or by a representative appointed for the corporation, either: (i) at the registered office of MindMed at any time up to and including the last business day preceding the day of the AGM or any adjournment(s) thereof, at One World Trade Center, Suite 8500, New York, New York 10007; or (ii) with the chairman of the AGM on the day of the AGM or any adjournment(s) thereof before any vote in respect of which the proxy has been given has been taken; or
(b) revoking the proxy in any other manner permitted by law.
A non-registered shareholder may revoke a form of proxy or VIF given to an intermediary or Broadridge Investor Communications (or any such other service company) at any time by submitting another properly completed form of proxy or VIF, as the latest form of proxy or VIF will automatically revoke any previous one already submitted, or by written notice to the intermediary in accordance with the instructions given to the non-registered shareholder by its intermediary.
Neither FCM, nor any of its directors or officers, or any associates or affiliates of the foregoing, nor any of FCM's nominees for election to the Board at the AGM, or their respective associates or affiliates, has: (i) any material interest, direct or indirect, in any transaction since the beginning of MindMed's most recently completed financial year or in any proposed transaction that has materially affected or would materially affect MindMed or any of its subsidiaries; or (ii) any material interest, direct or indirect, by way of beneficial ownership of securities or otherwise, in any matter currently known to be acted on at the upcoming meeting of MindMed shareholders, other than the election of directors; except that on August 31, 2020, Dr. Scott Freeman entered into a consulting agreement with MindMed, which, among other things, granted Dr. Scott Freeman 26,389 vested options with a strike price of CAD$4.95 per share and 16,667 unvested options with a strike price of CAD$4.95 per share.
The registered address of MindMed is located at One World Trade Center, Suite 8500, New York, New York, 10007. A copy of this communication may be obtained on MindMed’s SEDAR profile at https://t.co/Vz2979jwzV.

[Freeman Capital Management LLC @capital_freeman]

$MNMD

This slide from our presentation highlights that MindMed has been the worst performing stock of its peer group since Barrow took over. The difference in stock value between MindMed and Compass Pathway if you invested $1,000: is $50 for MindMed and $270 for Compass. That is, your Compass would be worth 5x more.

Visit https://t.co/AjhjgqXCVz for the full presentation

[Freeman Capital Management LLC @capital_freeman]

@0xfoobar Remember in a bank run it’s perfectly rational to join in

[Freeman Capital Management LLC @capital_freeman]

@LaMonicaBuzz Probably not. Section 230 is pretty strong. Option volume suggests nefarious actors may have been involved so hopefully the SEC looks into it.

[Freeman Capital Management LLC @capital_freeman]

Today, FCM announces that it has formally filed a complaint with @SECGov and demands a Federal investigation into the allegations at $MNMD

https://t.co/TCO8IpSwkk

[Freeman Capital Management LLC @capital_freeman]

@BeekoJoe @lambolife6 @RobertBBarrow @mindmedco Sources close to MindMed say that MindMed has brought in a very expensive PR firm. Wouldn’t be surprised.

[Freeman Capital Management LLC @capital_freeman]

Putting the "bail" in Robert Bailey Barrow. $MNMD

[Freeman Capital Management LLC @capital_freeman]

@RobertBBarrow must recuse himself. In FCM’s latest letter to the Board we detail the intersection of various public records with MindMed.

Highly recommend anyone interested or invested in $MNMD read this: https://t.co/seLbhxrWTr

[Freeman Capital Management LLC @capital_freeman]

Today, FCM sent a letter to $MNMD shareholders in regards to Mr. Robert Barrow's recent interview.

The full text of the letter and its exhibits is available at: https://t.co/8GVwV9q3Qj

[Freeman Capital Management LLC @capital_freeman]

@gzaha @RobertBBarrow His statement would still be false.

[Freeman Capital Management LLC @capital_freeman]

Fact Checking @RobertBBarrow: A thread.

Barrow falsely claims that MindMed stock price was up 30 days after the reverse stock split (which is 9/29). It was down 70%.

[Freeman Capital Management LLC @capital_freeman]

Barrow erroneously states he has not made a discretionary sale of MindMed stock.

“Sell to cover election” is an election and is discretionary.

Barrow’s vesting tax implications are less than 15% of his cash compensation last year.

[Freeman Capital Management LLC @capital_freeman]

When Barrow says MindMed used Liechti data to skip a Phase I trial for LSD in anxiety, but MindMed press release says otherwise (16:04)

[Freeman Capital Management LLC @capital_freeman]

Barrow misrepresented the Liechti lab studies.

Professor Liechti did one safety study in healthy volunteers and two studies in anxiety patients.

Barrow misrepresented that MindMed does not have patient data.

[Freeman Capital Management LLC @capital_freeman]

@robertbbarrow referred to the financing announced on 9/27 as closed; but no current report exists from MindMed on this.

Is this material information that should have been previously disclosed?

Potential issues with Regulation FD.

Troubling…

Only 10% in.

[Freeman Capital Management LLC @capital_freeman]

@traderTVLIVE Thank you TradeTV for hosting me. I think its great that shareholders are able to hear our thoughts and path forward with respect to $MNMD

[Freeman Capital Management LLC @capital_freeman]

Today, I sent a letter to @mindmedco CEO Robert Barrow proposing a debate between our sides. I think this would be incredibly helpful to the betterment of MindMed.
Full text available at https://t.co/i2X1wq6rps

[Freeman Capital Management LLC @capital_freeman]

@WookCapital FCM and Jake Freeman certainly agree that we should increase the I bond purchase cap. It should increase with the inflation it indexes for.

[Freeman Capital Management LLC @capital_freeman]

This is just the beginning. Details to come this week. $MNMD

[Freeman Capital Management LLC @capital_freeman]

Unlike Management, FCM is willing to provide $MNMD its services at no cost.